Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

In this randomized trial involving patients with noncystic fibrosis bronchiectasis, the rate of pulmonary exacerbations over a 52-week period was lower with brensocatib (10 mg or 25 mg per day) than with placebo.

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 392; číslo 16; s. 1569 - 1581
Hlavní autori:	Chalmers, James D., Burgel, Pierre-Régis, Daley, Charles L., De Soyza, Anthony, Haworth, Charles S., Mauger, David, Loebinger, Michael R., McShane, Pamela J., Ringshausen, Felix C., Blasi, Francesco, Shteinberg, Michal, Mange, Kevin, Teper, Ariel, Fernandez, Carlos, Zambrano, Migdalia, Fan, Chunpeng, Zhang, Xiangmin, Metersky, Mark L.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Massachusetts Medical Society 24.04.2025
Predmet:	Administration, Oral Adolescent Adolescent Medicine Adolescents Adult Adults Aged Aged, 80 and over Allergy Antibiotics Benzoxazoles Bronchiectasis Bronchiectasis - diagnosis Bronchiectasis - drug therapy Bronchiectasis - immunology Bronchiectasis - physiopathology Childhood Diseases Clinical Medicine Clinical practice guidelines Critical Care Critical Care General Cystic fibrosis Dipeptidyl-Peptidase IV Inhibitors - administration & dosage Dipeptidyl-Peptidase IV Inhibitors - adverse effects Disease Disease Progression Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Forced Expiratory Volume - drug effects Forced Expiratory Volume - physiology Humans Immunology Infections Infectious Disease Infectious Disease General Inflammation Inflammatory Disease Interstitial Lung Disease Keratosis - chemically induced Keratosis - epidemiology Leukocytes (neutrophilic) Male Middle Aged Neutrophils Neutrophils - drug effects Neutrophils - enzymology Neutrophils - immunology Outpatient-Based Clinical Medicine Oxazepines Pediatrics Pediatrics General Placebos Proteases Pulmonary Quality of Life Questionnaires Serine proteinase Teenagers Treatment Outcome Young Adult
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	In this randomized trial involving patients with noncystic fibrosis bronchiectasis, the rate of pulmonary exacerbations over a 52-week period was lower with brensocatib (10 mg or 25 mg per day) than with placebo.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2411664